| Model 1a
| Model 2a
| Model 3a
|
---|
OR | 95% CI |
p
| OR | 95% CI |
p
| OR | 95% CI |
p
|
---|
N° of disease flares | 2.5 | 1.4–4.5 | 0.003 | | |
Sustained remission | | 0.4 | 0.1, 0.9 | 0.031 | |
DAS28 | | | 2.1 | 1.3–3.3 | 0.002 |
N° of DMARDs/patient | 2.9 | 1.6–5.3 | 0.001 | 1.7 | 1.0–3.1 | 0.06 | 1.7 | 1–3.0 | 0.05 |
Persistence < 50% | 3.01 | 1.3–7.3 | 0.011 | 2.2 | 1.0–5.2 | 0.06 | 1.9 | 1–4.6 | 0.06 |
- Model 1: Comorbidities (or age), SF36, disease flares, number of DMARDs/patient and persistence <50%
- Model 2: Age (or comorbidities), remission, number of DMARDs/patient and persistence <50% and number of visits
- Model 3: Age (or comorbidities), DAS28-ESR, number of DMARDs/patient and persistence <50% and number of visits
-
aData presented as HR, 95% CI, p-value. Ninety patients were included, 30 of them with HDO and 60 with complete follow-up